Basilea Pharmaceutica to get $1.25m license fee from Pfizer
Switzerland’s Basilea Pharmaceutica Ltd. will receive $1.25 million from its partner Pfizer Inc. after the latter exceeded the sales target for a licensed.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Switzerland’s Basilea Pharmaceutica Ltd. will receive $1.25 million from its partner Pfizer Inc. after the latter exceeded the sales target for a licensed.
HQ Team April 4, 2024: The USFDA approved Swiss-based Basilea Pharmaceutica International’s Zevtera injection for the treatment of staphylococcus aureus bloodstream infections and.
HQ Team September 28, 2023: Swiss biotechnology company, Basilea Pharmaceutica’s last stage trials of ceftobiprole to treat bacterial bloodstream infections have shown favourable.